Vanguard Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.1M Sell
2,906,793
-58,069
-2% -$297K ﹤0.01% 2543
2026
Q2
$13.8M Sell
2,964,862
-281,262
-9% -$1.4M ﹤0.01% 2639
2026
Q1
$17.5M Buy
+3,246,124
New +$14.9M ﹤0.01% 2422

Other funds holding AVIR

Vanguard Capital Management's AVIR Position: Q3 2026 in Review

Vanguard Capital Management reduced its Atea Pharmaceuticals (AVIR) stake by 2% in Q3 2026, selling an estimated $297K and leaving 2,906,793 shares worth $15.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2543.

Vanguard Capital Management first reported a position in AVIR in Q1 2026 and has held it in 3 quarters since. The position peaked at $17.5M in Q1 2026. 127 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

  • Vanguard Capital Management held 2,906,793 shares of Atea Pharmaceuticals worth $15.1M as of Q3 2026.
  • Vanguard Capital Management sold 58,069 Atea Pharmaceuticals shares in Q3 2026, an estimated $297K.
  • Atea Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2543 holding.
  • Vanguard Capital Management first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Atea Pharmaceuticals position peaked at $17.5M in Q1 2026.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.